Forvisirvat
Forvisirvat is a sirtuin-6 activator which is under development for the treatment of major [depressive disorder] and schizophrenia. It is taken by mouth. As of January 2025, forvisirvat is in Phases of [clinical research#Phase II|phase 2]/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia. It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.